SEC Tracker
Get the app

Priveterra Acquisition AEON

Priveterra Acquisition FY 2022: net income $6.4M, down 22%; diluted EPS −$27.36

Form
10-K/A
Filed
Period
Importance
Routine
Document
10-K/A

Key figures from this report

These are the numbers Priveterra Acquisition reported for the year ended Dec 31, 2022, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Net income$6.4M−22% from $8.2M in FY 202110-K/A income statement, on EDGAR
  2. Diluted EPS−$27.36No year-earlier figure tagged. Split-adjusted, as the tables show it; the filing reported −$0.3810-K/A income statement, on EDGAR
  3. Cash and cash equivalents$9.7M+1859% from $497K in FY 202110-K/A balance sheet, on EDGAR
  4. Cash from operations−$981KAgainst −$1.5M in FY 202110-K/A cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Priveterra Acquisition files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float under $300M, nearest public float first, as each company reports it on its annual report cover.

  1. GT Biopharma GTBP public float $9M, Jun 30, 2025
  2. TherapeuticsMD TXMD public float $9M, Jun 30, 2025
  3. Oncotelic Therapeutics OTLC public float $9M, Jun 30, 2025
  4. Alaunos Therapeutics TCRT public float $10M, Jun 30, 2025
  5. Traws Pharma ONTX public float $10M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.